GOLGA6L22

Across TCGA pan-cancer cohorts, GOLGA6L22 RNA is linked to patient survival in 13 of 34 cancer types, making it the most broadly survival-associated GOLGA6L22 data layer compared with 2 for mutation status.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where higher GOLGA6L22 RNA is associated with worse disease-free survival. In most high-consensus cancer types, elevated GOLGA6L22 expression acts as an unfavorable survival marker, although some lineages such as ESCA and ACC show a favorable association.

KIRC, UVM, and STAD are the cancer types where GOLGA6L22 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
KIRC	DFS	Tertile	All	0.449	0.678	<.001	69	view →
UVM	DFS	Tertile	III,IV	0.071	0.636	<.001	54	view →
STAD	OS	Tertile	All	0.596	0.800	.012	45	view →
ESCA	DFS	Median	III,IV	0.649	0.338	.002	43	view →
LIHC	OS	Tertile	III,IV	0.105	0.625	<.001	33	view →
LAML	DFS	Quartile	All	0.166	0.452	<.001	32	view →
BRCA	DFS	Tertile	III,IV	0.255	0.514	.007	24	view →
LUAD	DFS	Tertile	IV	0.223	0.710	.043	18	view →
ACC	DFS	Tertile	IV	0.800	0.247	.004	9	view →
THCA	DFS	Tertile	IV	0.617	0.899	.010	9	view →
READ	OS	Tertile	All	1.000	0.893	.042	9	view →
LUSC	DFS	Median	IV	0.827	0.134	.024	6	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 13 lineages.

GOLGA6L22–KIRC (DFS)

Open the KIRC breakdown →